Influence of the CCK-antagonist loxiglumide on bile-induced experimental pancreatitis

[1]  W. Creutzfeldt,et al.  Camostate (FOY-305) improves the therapeutic effect of peritoneal lavage on taurocholate induced pancreatitis. , 1990, Gut.

[2]  M. Otsuki,et al.  Effect of a New Cholecystokinin Receptor Antagonist Loxiglumide on Acute Pancreatitis in Two Experimental Animal Models , 1990, Pancreas.

[3]  A. Saluja,et al.  Failure of a Potent Cholecystokinin Antagonist to Protect Against Diet‐Induced Pancreatitis in Mice , 1989, Pancreas.

[4]  A. Saluja,et al.  Experimental pancreatitis is mediated by low-affinity cholecystokinin receptors that inhibit digestive enzyme secretion. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[5]  K. Zucker,et al.  Cholecystokinin augmentation of 'surgical' pancreatitis. Benefits of receptor blockade. , 1989, Archives of surgery.

[6]  S. Bank,et al.  Effects of the cholecystokinin receptor antagonist L-364,718 on experimental pancreatitis in mice. , 1989, Gastroenterology.

[7]  B. Göke,et al.  Effect of FOY-305 (camostate) on severe acute pancreatitis in two experimental animal models. , 1989, Gastroenterology.

[8]  H. Shinya,et al.  Possible role of cholecystokinin in the development of acute pancreatitis in rats. , 1989, Nihon geka hokan. Archiv fur japanische Chirurgie.

[9]  I. Renner,et al.  Asperlicin, A Nonpeptidal Cholecystokinin Receptor Antagonist, Attenuates Sodium Taurocholate‐Induced Acute Pancreatitis in Rats , 1988, Pancreas.

[10]  S. Tani.  Experimental acute pancreatitis induced by excessive doses of caerulein in rats; protective and therapeutic effects of trypsin inhibitor urinastatin and CCK receptor antagonist CR1392. , 1988, The Kobe journal of medical sciences.

[11]  I. Ihse,et al.  Proglumide treatment in bile-induced acute experimental pancreatitis , 1988, International journal of pancreatology : official journal of the International Association of Pancreatology.

[12]  U. Stenram,et al.  Effects of the specific cholecystokinin antagonist L 364,718 in experimental acute pancreatitis in the rat. , 1988, European surgical research. Europaische chirurgische Forschung. Recherches chirurgicales europeennes.

[13]  W. Steinberg,et al.  Treatment of acute pancreatitis: Comparison of animal and human studies , 1987 .

[14]  L. Rovati,et al.  Pharmacological properties of lorglumide as a member of a new class of cholecystokinin antagonists. , 1987, Arzneimittel-Forschung.

[15]  F. Makovec,et al.  Loxiglumide protects against experimental pancreatitis. , 1987, Arzneimittel-Forschung.

[16]  P. Lankisch,et al.  Bile-induced acute experimental pancreatitis. , 1987, Scandinavian journal of gastroenterology.

[17]  P. Lankisch,et al.  Influence of buprenorphine on acute experimental pancreatitis , 1987, Research in experimental medicine. Zeitschrift fur die gesamte experimentelle Medizin einschliesslich experimenteller Chirurgie.

[18]  F. Makovec,et al.  Protective effect of CR 1409 (cholecystokinin antagonist) on experimental pancreatitis in rats and mice , 1986, Peptides.

[19]  L. Ferrell,et al.  Beneficial effects of cholecystokinin-receptor blockade and inhibition of proteolytic enzyme activity in experimental acute hemorrhagic pancreatitis in mice. Evidence for cholecystokinin as a major factor in the development of acute pancreatitis. , 1986, The Journal of clinical investigation.

[20]  L. Ferrell,et al.  Caerulein-induced acute necrotizing pancreatitis in mice: protective effects of proglumide, benzotript, and secretin. , 1985, Gastroenterology.

[21]  W. Rick,et al.  Kinetischer Test zur Bestimmung der Serumlipaseaktivität , 1969 .

[22]  William W. Cohen,et al.  The preparation and properties of two new chromogenic substrates of trypsin. , 1961, Archives of biochemistry and biophysics.